Takara Bio Inc. (4974.T)
JPY 1002.0
(-0.2%)
JPY 1002.0
(-0.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.48 Billion JPY | -90.76% |
| 2022 | 16.01 Billion JPY | -19.33% |
| 2021 | 19.84 Billion JPY | 107.91% |
| 2020 | 9.54 Billion JPY | 149.99% |
| 2019 | 3.81 Billion JPY | 4.43% |
| 2018 | 3.65 Billion JPY | 56.62% |
| 2017 | 2.33 Billion JPY | 72.71% |
| 2016 | 1.35 Billion JPY | 1.35% |
| 2015 | 1.33 Billion JPY | 38.53% |
| 2014 | 963 Million JPY | -34.49% |
| 2013 | 1.47 Billion JPY | 0.55% |
| 2012 | 1.46 Billion JPY | 42.91% |
| 2011 | 1.02 Billion JPY | 69.09% |
| 2010 | 605 Million JPY | 2.37% |
| 2009 | 591 Million JPY | -7.94% |
| 2008 | 642 Million JPY | -5.45% |
| 2007 | 679 Million JPY | 112.19% |
| 2006 | 320 Million JPY | 130.25% |
| 2005 | -1.05 Billion JPY | 17.47% |
| 2004 | -1.28 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.04 Billion JPY | -178.96% |
| 2023 Q4 | 1.32 Billion JPY | 242.58% |
| 2023 Q3 | -930 Million JPY | -221.57% |
| 2023 Q2 | 765 Million JPY | 139.81% |
| 2023 Q1 | 319 Million JPY | -77.49% |
| 2023 FY | 1.48 Billion JPY | -90.76% |
| 2022 Q3 | 6.05 Billion JPY | 30.79% |
| 2022 FY | 16.01 Billion JPY | -19.33% |
| 2022 Q1 | 3.9 Billion JPY | -28.77% |
| 2022 Q2 | 4.63 Billion JPY | 18.53% |
| 2022 Q4 | 1.41 Billion JPY | -76.61% |
| 2021 Q2 | 3.98 Billion JPY | -33.88% |
| 2021 Q3 | 4.35 Billion JPY | 9.31% |
| 2021 FY | 19.84 Billion JPY | 107.91% |
| 2021 Q4 | 5.48 Billion JPY | 25.95% |
| 2021 Q1 | 6.02 Billion JPY | 57.68% |
| 2020 Q4 | 3.82 Billion JPY | 10.69% |
| 2020 Q2 | 1.87 Billion JPY | 362.87% |
| 2020 FY | 9.54 Billion JPY | 149.99% |
| 2020 Q1 | 404 Million JPY | -63.64% |
| 2020 Q3 | 3.45 Billion JPY | 84.6% |
| 2019 FY | 3.81 Billion JPY | 4.43% |
| 2019 Q2 | 484 Million JPY | -69.58% |
| 2019 Q1 | 1.59 Billion JPY | 1.4% |
| 2019 Q3 | 633 Million JPY | 30.79% |
| 2019 Q4 | 1.11 Billion JPY | 75.51% |
| 2018 Q2 | 688 Million JPY | -33.33% |
| 2018 Q4 | 1.56 Billion JPY | 326.36% |
| 2018 Q3 | 368 Million JPY | -46.51% |
| 2018 Q1 | 1.03 Billion JPY | -18.55% |
| 2018 FY | 3.65 Billion JPY | 56.62% |
| 2017 Q3 | 766 Million JPY | 173.57% |
| 2017 Q2 | 280 Million JPY | 1172.73% |
| 2017 Q1 | 22 Million JPY | 110.53% |
| 2017 Q4 | 1.26 Billion JPY | 65.4% |
| 2017 FY | 2.33 Billion JPY | 72.71% |
| 2016 Q2 | 382 Million JPY | 34.04% |
| 2016 Q3 | 894 Million JPY | 134.03% |
| 2016 FY | 1.35 Billion JPY | 1.35% |
| 2016 Q4 | -209 Million JPY | -123.38% |
| 2016 Q1 | 285 Million JPY | -60.47% |
| 2015 Q2 | 181 Million JPY | 602.78% |
| 2015 FY | 1.33 Billion JPY | 38.53% |
| 2015 Q4 | 721 Million JPY | 54.06% |
| 2015 Q3 | 468 Million JPY | 158.56% |
| 2015 Q1 | -36 Million JPY | -103.44% |
| 2014 Q3 | -488 Million JPY | -226.42% |
| 2014 Q4 | 1.04 Billion JPY | 314.55% |
| 2014 FY | 963 Million JPY | -34.49% |
| 2014 Q1 | 18 Million JPY | -98.06% |
| 2014 Q2 | 386 Million JPY | 2044.44% |
| 2013 Q3 | 315 Million JPY | -34.51% |
| 2013 Q4 | 928 Million JPY | 194.6% |
| 2013 FY | 1.47 Billion JPY | 0.55% |
| 2013 Q1 | -254 Million JPY | -133.91% |
| 2013 Q2 | 481 Million JPY | 289.37% |
| 2012 Q2 | 209 Million JPY | 99.05% |
| 2012 Q4 | 749 Million JPY | 87.72% |
| 2012 Q1 | 105 Million JPY | -80.0% |
| 2012 FY | 1.46 Billion JPY | 42.91% |
| 2012 Q3 | 399 Million JPY | 90.91% |
| 2011 Q3 | 275 Million JPY | 10.44% |
| 2011 Q1 | -26 Million JPY | -104.66% |
| 2011 Q4 | 525 Million JPY | 90.91% |
| 2011 FY | 1.02 Billion JPY | 69.09% |
| 2011 Q2 | 249 Million JPY | 1057.69% |
| 2010 Q2 | 100 Million JPY | 142.74% |
| 2010 FY | 605 Million JPY | 2.37% |
| 2010 Q4 | 558 Million JPY | 208.29% |
| 2010 Q3 | 181 Million JPY | 81.0% |
| 2010 Q1 | -234 Million JPY | -174.52% |
| 2009 Q2 | 161 Million JPY | 231.97% |
| 2009 Q4 | 314 Million JPY | 31.93% |
| 2009 Q3 | 238 Million JPY | 47.83% |
| 2009 FY | 591 Million JPY | -7.94% |
| 2009 Q1 | -122 Million JPY | -113.17% |
| 2008 Q3 | 41 Million JPY | 125.63% |
| 2008 Q2 | -160 Million JPY | 0.0% |
| 2008 FY | 642 Million JPY | -5.45% |
| 2008 Q4 | 926 Million JPY | 2158.54% |
| 2007 FY | 679 Million JPY | 112.19% |
| 2006 FY | 320 Million JPY | 130.25% |
| 2005 FY | -1.05 Billion JPY | 17.47% |
| 2004 FY | -1.28 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | -285.417% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 380.881% |
| GNI Group Ltd. | 8.09 Billion JPY | 81.715% |
| Linical Co., Ltd. | 338.26 Million JPY | -337.525% |
| Trans Genic Inc. | 4.08 Million JPY | -36130.11% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 202.924% |
| Soiken Holdings Inc. | -662.2 Million JPY | 323.496% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | -971.261% |
| AnGes, Inc. | -7.43 Billion JPY | 119.899% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 214.895% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 120.576% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | -692.741% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 289.743% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 228.372% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 222.415% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 282.174% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 557.267% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 221.31% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 204.073% |
| PeptiDream Inc. | 3.03 Billion JPY | 51.249% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 176.347% |
| Ribomic Inc. | -1.02 Billion JPY | 244.498% |
| SanBio Company Limited | -2.64 Billion JPY | 155.976% |
| Healios K.K. | -3.82 Billion JPY | 138.713% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 226.703% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 199.355% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 203.54% |
| StemRIM | -2.02 Billion JPY | 173.195% |
| CellSource Co., Ltd. | 923.14 Million JPY | -60.322% |
| FunPep Company Limited | -933.41 Million JPY | 258.557% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 273.271% |
| Stella Pharma Corporation | -763.74 Million JPY | 293.781% |
| TMS Co., Ltd. | -960.04 Million JPY | 254.16% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 230.972% |
| Cuorips Inc. | -632.18 Million JPY | 334.109% |
| K Pharma,Inc. | 260.33 Million JPY | -468.509% |
| ReproCELL Incorporated | -31.41 Million JPY | 4811.125% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | -5510.736% |
| StemCell Institute Inc. | 310.98 Million JPY | -375.913% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | -933.743% |
| CellSeed Inc. | -846.53 Million JPY | 274.831% |